Phase 1 dose escalation study of FGFR4 inhibitor in combination with pembrolizumab in advanced solid tumors patients

OBJECTIVE: Inhibition of fibroblast growth factor (FGF) 19‐FGF Receptor 4 (FGFR4) signaling demonstrates potent anticancer activity. EVER4010001 is a highly selective FGFR4 inhibitor and pembrolizumab is approved for the treatment of several solid tumors. This study determined the maximum tolerated...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Jianming, Cui, Jiuwei, Jiang, Haiping, Zeng, Yan, Cong, Xiuyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134273/
https://www.ncbi.nlm.nih.gov/pubmed/36622048
http://dx.doi.org/10.1002/cam4.5532

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134273/
https://www.ncbi.nlm.nih.gov/pubmed/36622048
http://dx.doi.org/10.1002/cam4.5532

Ejemplares similares